Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 September 2019 | Story Leonie Bolleurs | Photo Leonie Bolleurs
student dialogue
Dialogues presented by the Office for International Affairs provide a safe space for people to voice their opinions, to learn, and to engage. Here are, from the left: Montsi Ramonaheng, third-year BSc student majoring in Biochemistry and Genetics; Lebohang Lesenyeno, third-year LLB student; Motsaathebe Serekoane, Lecturer in Anthropology; and Bulelwa Moikwatlhai from the Office for International Affairs.

Will the creation of one African country solve the problem of xenophobia? 

This was the question raised at a recent dialogue session on the University of the Free State Bloemfontein Campus.

Most attendees believed the concept of ‘one Africa’ implied that only one language and one dominant culture would be needed – resulting in the spirit of multiculturalism ceasing to exist. When one speaks of a united Africa, it means that the continent recognises the diversity of its cultures and embraces these diversities. It was concluded that one Africa was not a solution to ending xenophobia.

Awareness of xenophobia from a human rights perspective

The Office for International Affairs hosted the two-dialogue series aimed at addressing an array of social issues such as xenophobia, cultural appropriation, and xenocentrism. They wanted to demonstrate the influence these issues have – not only on the mindsets of individuals, but also on how it can contribute towards the development of an unjust society devoid of embracing difference.

The first session was titled: Burn the Phobia, with the theme: ‘We are all foreigners somewhere’. The aim of this dialogue was to create awareness of xenophobia from a human rights perspective. 

Recently, a second dialogue session was presented, with the theme ‘Appropriation vs Xenocentrism’. According to Bulelwa Moikwatlhai, Officer in the Office for International Affairs, the purpose of this session was to encourage people to appreciate their own cultures and to respect other peoples’ cultures.

“We wanted to critically discuss cultural appropriation versus xenocentrism in an attempt to find a human response that is inclusive in nature,” says Moikwatlhai.

Direct outflow of UFS Integrated Transformation Plan

The lecture was presented by Motsaathebe Serekoane, Lecturer in the Department of Anthropology at the UFS, who urged attendees to always keep it authentic. He also stated that, as boundaries between the North and the South collapsed and knowledge flowed in and out, knowledge from the South was not taken seriously. 

“We lost ourselves within what happened in the North. We want to be appropriate and we want what they have, because it is more beautiful than what we have. We need to find something in Africa that will define us as African,” he says. 

These dialogues are a build-up to the International Cultural Diversity Festival that will take place at the Thakaneng Bridge on 13 September 2019 from 12:00 to 14:00.

The dialogue is a direct outflow of the university’s Integrated Transformation Plan. “We strive to cultivate a culture where everyone feels welcome and comfortable. We want to create common ground for international and South African students to get together and to collaboratively discuss issues from both parties in order to find innovative solutions to student challenges,” indicates Moikwatlhai.

Much of what is learnt in these sessions is used for reflection in order to improve the overall student experience. According to Miokwatlhai, it is essential to ensure that all processes related to students are structured to be socially just and inclusive. 

“As an institution of higher learning, we need to continuously create such platforms so that we have rich engagements about pertinent issues that affect the UFS community, and find human solutions to overcome barriers,” she concludes.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept